Lymphoma Therapy Now Approved For Australian Patients With Diffuse Large B-Cell Lymphoma; Minjuvi Provisionally Approved By Therapeutic Goods Administration
Portfolio Pulse from Happy Mohamed
The Therapeutic Goods Administration (TGA) in Australia has provisionally approved MINJUVI (tafasitamab), a therapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The therapy is marketed by Specialised Therapeutics (ST) under an exclusive distribution arrangement with Incyte (NASDAQ:INCY). The approval is a significant regulatory milestone for ST and is expected to address unmet needs in rare patient populations.
June 27, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Incyte's partnership with Specialised Therapeutics for the distribution of MINJUVI in Australia could potentially boost its revenues as the drug has been approved for use in the country.
The approval of MINJUVI in Australia opens up a new market for Incyte, which could lead to increased sales and revenues. Given that the drug is being marketed under an exclusive distribution arrangement with Specialised Therapeutics, Incyte stands to benefit directly from this approval.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75